Bioventix (BVXP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bioventix (BVXP) has a cash flow conversion efficiency ratio of 0.402x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX4.44 Million ≈ $539.88 USD) by net assets (GBX11.04 Million ≈ $1.34K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BVXP market cap for the company's overall valuation and market capitalisation.
Bioventix - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Bioventix's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bioventix Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bioventix ranked by their cash flow conversion efficiency. Explore Bioventix cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pathfinder Ventures Inc
V:RV
|
0.233x |
|
TH1NG AB
ST:TH1NG
|
0.336x |
|
Duros S.A.
AT:DUR
|
-0.182x |
|
Avation PLC
LSE:AVAP
|
-0.005x |
|
GACM Technologies Limited
NSE:GATECHDVR
|
N/A |
|
SEALAND CAP. GA. LS-0001
F:7KM
|
N/A |
|
FKS Food Sejahtera Tbk PT
JK:AISA
|
0.005x |
|
Global Energy Metals Corp
V:GEMC
|
-0.028x |
Annual Cash Flow Conversion Efficiency for Bioventix (2011–2025)
The table below shows the annual cash flow conversion efficiency of Bioventix from 2011 to 2025. View current stock price of Bioventix for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | GBX11.55 Million ≈ $1.41K |
GBX7.03 Million ≈ $855.57 |
0.609x | -12.44% |
| 2024-06-30 | GBX12.00 Million ≈ $1.46K |
GBX8.34 Million ≈ $1.02K |
0.695x | +6.11% |
| 2023-06-30 | GBX12.06 Million ≈ $1.47K |
GBX7.90 Million ≈ $961.62 |
0.655x | +2.42% |
| 2022-06-30 | GBX11.82 Million ≈ $1.44K |
GBX7.56 Million ≈ $920.03 |
0.640x | +18.74% |
| 2021-06-30 | GBX11.82 Million ≈ $1.44K |
GBX6.37 Million ≈ $774.79 |
0.539x | -12.67% |
| 2020-06-30 | GBX12.52 Million ≈ $1.52K |
GBX7.72 Million ≈ $939.79 |
0.617x | +13.63% |
| 2019-06-30 | GBX10.83 Million ≈ $1.32K |
GBX5.88 Million ≈ $715.12 |
0.543x | +0.94% |
| 2018-06-30 | GBX11.01 Million ≈ $1.34K |
GBX5.92 Million ≈ $720.55 |
0.538x | +37.89% |
| 2017-06-30 | GBX10.14 Million ≈ $1.23K |
GBX3.96 Million ≈ $481.44 |
0.390x | +0.93% |
| 2016-06-30 | GBX8.21 Million ≈ $998.60 |
GBX3.17 Million ≈ $385.91 |
0.386x | +18.62% |
| 2015-06-30 | GBX6.58 Million ≈ $801.10 |
GBX2.15 Million ≈ $260.99 |
0.326x | -3.36% |
| 2014-06-30 | GBX5.24 Million ≈ $637.09 |
GBX1.77 Million ≈ $214.78 |
0.337x | +5.70% |
| 2013-06-30 | GBX4.20 Million ≈ $511.61 |
GBX1.34 Million ≈ $163.17 |
0.319x | -14.04% |
| 2012-06-30 | GBX3.34 Million ≈ $406.34 |
GBX1.24 Million ≈ $150.76 |
0.371x | +29.66% |
| 2011-06-30 | GBX2.68 Million ≈ $325.76 |
GBX766.14K ≈ $93.22 |
0.286x | -- |
About Bioventix
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flo… Read more